ClinicalTrials.gg
RecruitingNCT07024823Updated Nov 12, 2026

A Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants

A Phase 1 interventional study of AZD4248 and Placebo in Chronic Kidney Disease, sponsored by AstraZeneca. Recruiting at 5 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 12, 2026Primary completion movedStudy completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Renal Insufficiency, Chronic by AstraZeneca — 6 open to participants now, 11 under way, 5 of them phase 3. Renal Insufficiency, Chronic · AstraZeneca.

Planned enrollment
18th of 38
192 · median 170
Started
2025
with 4 others
Phase 1
16 of 54
1 open now
Primary completion
2027-01
later than 2 of 10 live
Registered
47th of 54
by date

Among the 54 studies in Renal Insufficiency, Chronic by AstraZeneca, this one is the 18th largest by planned enrollment of the 38 interventional ones that give a count, is one of 5 that started in 2025, is one of 16 in phase 1, reaches primary completion later than 2 of the 10 other live ones, and was the 47th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

6 of the 54 studies in Renal Insufficiency, Chronic by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Renal Insufficiency, Chronic by AstraZeneca, or all of them as a file.
02

Study summary

This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV) infusion. Additionally, the study investigates the non-interventional feasibility of home measurement of serum creatinine in participants with diabetic kidney disease (DKD), and the effect of multiple doses of AZD4248 on the PK of oral midazolam and metformin.

Read the detailed description

This is a Phase I, first in human (FIH), randomized, single-blind, placebo-controlled study of AZD4248 involving healthy participants (Parts A and B) and participants with DKD (Part C), to assess home measurements of creatinine in a prospective, non-interventional cohort in participants with DKD (Part D), and assess the effect of multiple doses of AZD4248 on the PK of oral midazolam and metformin in an open-label, fixed sequence design in healthy participants (Part E).

The study consists of 5 parts:

  • Part A: SAD. Part A will consist of Parts A1 (single ascending doses in healthy participants), A2 (single dose in healthy Chinese participants), and A3 (IV infusion in healthy participants).
  • Part B: MAD. Part B will consist of Parts B1 (multiple ascending doses in healthy participants) and B2 (multiple ascending doses in healthy participants of Japanese descent).
  • Part C: Multiple dosing in participants with DKD.
  • Part D: Multi-site, non-interventional, prospective cohort evaluation of home-based creatinine self-measurement in participants with DKD.
  • Part E: Open-label, fixed sequence assessment of drug-drug interactions in healthy participants.
03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • Type 2 Diabetes
  • Diabetic Kidney Disease
  • Multiple Ascending Dose
  • Single Ascending Dose
  • Creatinine
  • Drug-drug Interactions
  • Food Effect
  • Pharmacokinetics
  • Safety
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

- Healthy participants with suitable veins for cannulation or repeated venipuncture.

Parts A, B, and E:

  • Have a (BMI) between 18 and 30 kilograms per millimeter (kg/m2), inclusive.
  • For Chinese participants (Part A2): participants are to be Chinese, defined as having both parents and 4 grandparents who are Chinese. This includes second and third generation participants of Chinese descent whose parents or grandparents are living in a country other than China.
  • For Japanese participants (Part B2): participants are to be Japanese, defined as having both parents and 4 grandparents who are Japanese. This includes second and third generation participants of Japanese descent whose parents or grandparents are living in a country other than Japan.

Part C:

  • Have a BMI between 20 and 40 kg/m2, inclusive.
  • Have a diagnosis of diabetic kidney disease (DKD).
  • (HbA1c) of ≤ 10.5%.
  • Participants are required to be on a stable dose of angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for at least 6 weeks prior to Visit 1 and throughout the Screening Period. In addition, participants should be on stable doses of all other medication for ≥ 6 weeks before Screening.

Part D:

  • Have a BMI between 20 and 35 kg/m2, inclusive.
  • Have a diagnosis of DKD as defined by a) diagnosis of type 2 diabetes (T2D) b) values and c) urine albumin to creatinine ratio (UACR) values.
  • HbA1c of ≤ 10.5%.
  • Participants are required to be on a stable dose of ACEi or ARB for at least 6 weeks prior to Visit 1 and throughout the Screening Period. In addition, participants should be on stable doses of all other medication for ≥ 6 weeks before Screening.
  • Participants must be able and motivated to use the home creatinine device and smartphone independently by successfully performing the test without assistance from site staff.
  • Participants must be able to read and understand English sufficient to participate in site visits and home testing.

Key Exclusion Criteria:

  • History of any disease or disorder which may put the participant at risk because of participation in the study or influence the results.
  • Any positive result on Screening for serum surface antigen (HBsAg), hepatitis B core antibody (HBcAb), Hebpatitis C virus antibody (HCVab), or (HIV).

Parts A, B, and E:

  • History or presence of gastrointestinal, hepatic, or renal disease.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD4248.
  • Participants who have previously received AZD4248.

Part C:

  • History or presence of gastrointestinal, hepatic, or renal disease.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
  • History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD4248.
  • Use of drugs that are strong or moderate inhibitors/inducers or P-gp inhibitors from within 3 weeks before Screening until the end of the last sample collection.
  • Participants who have previously received AZD4248.
  • Participants on serum creatinine-altering drugs should be on long-term treatment at a stable dose prior to study entry.
  • Expected change of dosing regimen during the study.
  • History of clinically significant heart or vascular disease.
  • Class 2, 3, or 4 or history of hospitalization for heart failure within 6 months of screening.
  • Ventricular arrhythmias requiring treatment.
  • Amputation due to peripheral artery disease.
  • Severe as judged by the Investigator or hospitalization for exacerbation in the last 6 months.

Part D:

  • Participants on serum creatinine-altering drugs should be on long-term treatment at a stable dose prior to study entry.
  • Expected change of dosing regimen during the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Care provider)
Enrollment
192 participants (estimated)

Study arms

  • Experimental
    Part A1 SAD

    Participants will receive single ascending oral dose of AZD4248 or placebo.

    Drug: AZD4248 · Drug: Placebo

  • Experimental
    Part A2 SAD Chinese Cohort

    Participants will receive single oral dose of AZD4248 or placebo.

    Drug: AZD4248 · Drug: Placebo

  • Experimental
    Part A3 SAD IV Cohort

    Participants will receive single IV infusion of AZD4248 or placebo.

    Drug: AZD4248 · Drug: Placebo

  • Experimental
    Part B1 MAD

    Participants will receive multiple ascending oral doses of AZD4248 or placebo.

    Drug: AZD4248 · Drug: Placebo

  • Experimental
    Part B2 MAD Japanese

    Participants will receive multiple ascending oral doses of AZD4248 or placebo.

    Drug: AZD4248 · Drug: Placebo

  • Experimental
    Part C Multiple Dosing DKD

    Participants will receive multiple oral doses of AZD4248 or placebo.

    Drug: AZD4248 · Drug: Placebo

  • No intervention
    Part D Observational Cohort

    Participants will participate in home-based creatinine self-measurement.

  • Experimental
    Part E Drug-Drug Interaction Cohort

    Participants will receive a single dose of midazolam and metformin followed by multiple oral doses of AZD4248 with a single dose of midazolam and metformin.

    Drug: AZD4248 · Drug: Midazolam · Drug: Metformin

Interventions

  • DrugAZD4248

    AZD4248 will be administered orally.

  • DrugPlacebo

    Placebo will be administered orally.

  • DrugAZD4248

    AZD4248 will be administered via IV infusion.

  • DrugPlacebo

    Placebo will be administered via IV infusion.

  • Midazolam will be administered orally.

  • Metformin will be administered orally.

06

What researchers measure

Primary outcomes

  1. Parts A, B, and C: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    To assess the safety and tolerability of AZD4248 following single oral ascending doses or single IV administration to healthy participants and multiple oral ascending doses to healthy participants and participants with CKD and T2D (DKD).

    Time frame: From Day 1 to Follow Up visit (Part A: up to 12 days; Part B and C: up to 19 days)

  2. Part D: Intra- and inter-participant variability of estimated glomerular filtration rate (eGFR) derived from home self-testing device measurements

    To assess intra- and inter-participant variability of twice weekly home-based serum creatinine measurements.

    Time frame: Day 1 to Day 169

  3. Part E: Area under concentration-time curve from time 0 to infinity (AUCinf) for midazolam

    To assess the effect of AZD4248 on PK of midazolam and metformin.

    Time frame: Days 1-2, 4-5, 17 and 18

  4. Part E: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) for midazolam

    To assess the effect of AZD4248 on PK of midazolam and metformin.

    Time frame: Days 1-2, 4-5, 17 and 18

  5. Part E: Maximum observed drug concentration (Cmax) for midazolam

    To assess the effect of AZD4248 on PK of midazolam and metformin.

    Time frame: Days 1-2, 4-5, 17 and 18

  6. Part E: Ratio of Test treatment (AZD4248 + midazolam) to Reference (AZD4248) based on AUCinf (RAUCinf) of AZD4248

    To assess the effect of AZD4248 on PK of midazolam and metformin.

    Time frame: Days 1-2, 4-5, 17 and 18

  7. Part E: Ratio of Test treatment (AZD4248 + midazolam) to Reference (AZD4248) based on AUClast (RAUClast) of AZD4248

    To assess the effect of AZD4248 on PK of midazolam and metformin.

    Time frame: Days 1-2, 4-5, 17 and 18

  8. Part E: Ratio of Test treatment (AZD4248 + midazolam) to Reference (AZD4248) based on Cmax (RCmax) of AZD4248

    To assess the effect of AZD4248 on PK of midazolam and metformin.

    Time frame: Days 1-2, 4-5, 17 and 18

  9. Part E: Terminal elimination half-life (t½λz) for midazolam

    To assess the effect of AZD4248 on PK of midazolam and metformin.

    Time frame: Days 1-2, 4-5, 17 and 18

  10. Part E: Terminal rate constant (λz) for midazolam

    To assess the effect of AZD4248 on PK of midazolam and metformin.

    Time frame: Days 1-2, 4-5, 17 and 18

  11. Part E: Time to reach maximum observed concentration (tmax) for midazolam

    To assess the effect of AZD4248 on PK of midazolam and metformin.

    Time frame: Days 1-2, 4-5, 17 and 18

  12. Part E: AUCinf for metformin

    To assess the effect of AZD4248 on PK of midazolam and metformin.

    Time frame: Days 2-4, 6, and 7-16

  13. Part E: AUClast for metformin

    To assess the effect of AZD4248 on PK of midazolam and metformin.

    Time frame: Days 2-4, 6, and 7-16

  14. Part E: Cmax for metformin

    To assess the effect of AZD4248 on PK of midazolam and metformin.

    Time frame: Days 2-4, 6, and 7-16

  15. Part E: Ratio of Test treatment (AZD4248 + metformin) to Reference (AZD4248) based on AUCinf (RAUCinf) of AZD4248

    To assess the effect of AZD4248 on PK of midazolam and metformin.

    Time frame: Days 2-4, 6, and 7-16

  16. Part E: Ratio of Test treatment (AZD4248 + metformin) to Reference (AZD4248) based on AUClast (RAUClast) of AZD4248

    To assess the effect of AZD4248 on PK of midazolam and metformin.

    Time frame: Days 2-4, 6, and 7-16

  17. Part E: Ratio of Test treatment (AZD4248 + metformin) to Reference (AZD4248) based on Cmax (RCmax) of AZD4248

    To assess the effect of AZD4248 on PK of midazolam and metformin.

    Time frame: Days 2-4, 6, and 7-16

  18. Part E: Renal clearance (CLR) for metformin

    To assess the effect of AZD4248 on PK of midazolam and metformin.

    Time frame: Days 2-4, and 6-8

  19. Part E: t½λz for metformin

    To assess the effect of AZD4248 on PK of midazolam and metformin.

    Time frame: Days 2-4, 6, and 7-16

  20. Part E: λz for metformin

    To assess the effect of AZD4248 on PK of midazolam and metformin.

    Time frame: Days 2-4, 6, and 7-16

  21. Part E: tmax for metformin

    To assess the effect of AZD4248 on PK of midazolam and metformin.

    Time frame: Days 2-4, 6, and 7-16

Secondary outcomes

  1. Area under concentration-time curve from time 0 to infinity (AUCinf)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248. To assess the impact of food on the PK of AZD4248 following a single oral administration.

    Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19

  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248. To assess the impact of food on the PK of AZD4248 following a single oral administration.

    Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19

  3. Dose normalized AUClast (AUClast/D)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.

    Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17

  4. Dose normalized AUCinf (AUCinf/D)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.

    Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17

  5. Apparent total body clearance (CL/F)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.

    Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19

  6. Maximum observed drug concentration (Cmax)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248. To assess the impact of food on the PK of AZD4248 following a single oral administration.

    Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19

  7. Dose normalized Cmax (Cmax/D)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.

    Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17

  8. Terminal elimination half-life (t½λz)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.

    Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19

  9. Terminal rate constant (λz)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.

    Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19

  10. Time delay between drug administration and the first observed concentration (tlag)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.

    Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3; Part E: Days 4-5, and 17-19

  11. Time of last quantifiable concentration (tlast)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.

    Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19

  12. Time to reach maximum observed concentration (tmax)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248. To assess the impact of food on the PK of AZD4248 following a single oral administration.

    Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19

  13. Apparent volume of distribution based on the terminal phase (Vz/F)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.

    Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19

  14. Absolute bioavailability (F)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.

    Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3.

  15. Total body clearance (CL)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.

    Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17

  16. Volume of distribution at steady state (Vss)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.

    Time frame: Part A1 and A2: Days 1-7, Part A3: Days 1-3

  17. Area under concentration-time curve in the dose interval (AUCtau)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.

    Time frame: Part B: Days 1-17. Part C: Days 1-17

  18. Dose normalized AUCtau (AUCtau/D)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.

    Time frame: Part B: Days 1-17. Part C: Days 1-17

  19. Accumulation ratio for AUC (Rac AUC)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV adnminstration of AZD4248.

    Time frame: Part B: Days 1-17. Part C: Days 1-17

  20. Accumulation ratio for Cmax (Rac Cmax)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.

    Time frame: Part B: Days 1-17. Part C: Days 1-17

  21. Temporal change parameter (TCP)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.

    Time frame: Part B: Days 1-17. Part C: Days 1-17

  22. Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1-t2)]

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.

    Time frame: Part A: Days 1-2. Part B: Days 1-4 and 11-14. Part C: Days 1-4 and 11-14

  23. Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 [fe(t1-t2)]

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.

    Time frame: Part A: Days 1-2. Part B: Days 1-4 and 11-14. Part C: Days 1-4 and 11-14

  24. Renal clearance (CLR)

    To characterize the PK of AZD4248 following oral administration of single and multiple doses or a single IV administration of AZD4248.

    Time frame: Part A: Days 1-2. Part B: Days 1-4 and 11-14. Part C: Days 1-4 and 11-14

  25. Percentage change from baseline in plasma target engagement marker

    To evaluate the TE of AZD4248 by assessing reduction in plasma target engagement marker following single (oral or IV) and multiple oral dosing of AZD4248.

    Time frame: Part A: Days 1-5. Part B: Days 1-4 and 11-14. Part C: Days 1-4 and 11-14

  26. Part D: Intra- and inter-participant variability of eGFR derived from laboratory measurements

    To assess the intra- and inter-participant variability of monthly laboratory-based creatinine measurements.

    Time frame: Day 1 to Day 169

  27. Part D: Changes over longitudinal follow-up in participant-reported experience questionnaire on collective participant satisfaction, usability and device acceptability data

    To evaluate the usability, user satisfaction, and feasibility of delivering a home self-testing device and its accompanying smartphone application.

    Time frame: Day 1 to Day 169

  28. Part D: Summary of qualitative insights from optional individual in-depth interview samples

    To evaluate the usability, user satisfaction, and feasibility of delivering a self-testing, home self-testing device and its accompanying smartphone application.

    Time frame: Day 30 to Day 84

  29. Part D: Changes over longitudinal follow-up in site-based staff reported PTSFQ

    To assess clinical site staff-reported usability and satisfaction of delivering and management of the home self-testing device and software.

    Time frame: Day 1 to Day 169

  30. Part D: Estimated glomerular filtration rate (eGFR)

    To compare home-based serum creatinine measurements against the standard laboratory measurements.

    Time frame: Day 1 to Day 169

  31. Part D: Proportion of completed creatinine tests, with completed assessments

    To assess the rates of missing data due to missed tests or test errors.

    Time frame: Day 1 to Day 169

  32. Part E: Number of AEs and SAEs

    To assess the safety and tolerability of AZD4248 alone and in combination with midazolam and metformin.

    Time frame: From Day 1 to Follow Up visit (Part E: up to 24 days)

07

Study locations

4 of 5 sites recruiting
  • Research Site
    Glendale, California 91206, United States
    Recruiting
  • Research Site
    Chicago, Illinois 60643, United States
    Recruiting
  • Research Site
    Ann Arbor, Michigan 48109, United States
    Active, not recruiting

    Not enrolling at this site.

  • Research Site
    Saint Paul, Minnesota 55114, United States
    Recruiting
  • Research Site
    San Antonio, Texas 78215, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jan 2027, 19 months after the start.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 19 months is above that.

Counting every sponsor, half of 109 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Dec 2026 → Jan 2027 and completion Dec 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2025
First posted
Jun 17, 2025
StartActual
Jun 9, 2025
Primary completionEst.
Jan 29, 2027was Dec 2026
CompletionEst.
Jan 29, 2027was Dec 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 25, 2026→Jan 29, 2027
Nov 12, 2026
Study completion
Dec 25, 2026→Jan 29, 2027
Nov 12, 2026
Enrollment
124→192
Nov 12, 2026
Eligibility
3 criteria edited
What changed in the criteria
  • EditedParts A, B, and BE:
  • EditedAny positive result on Screening for serum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), Hebpatitis C virus antibody (HCVab), or human immunodeficiency virus (HIV).
  • EditedParts A, B, and BE:
Nov 12, 2026
Interventions
Added Drug: Midazolam·Drug: Metformin. Arms added: Part E Drug-Drug Interaction Cohort
Nov 12, 2026
Primary outcomes
19 added
What changed in the outcomes
  • AddedPart E: Area under concentration-time curve from time 0 to infinity (AUCinf) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
  • AddedPart E: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
  • AddedPart E: Maximum observed drug concentration (Cmax) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
  • AddedPart E: Ratio of Test treatment (AZD4248 + midazolam) to Reference (AZD4248) based on AUCinf (RAUCinf) of AZD4248Time frame: Days 1-2, 4-5, 17 and 18
  • AddedPart E: Ratio of Test treatment (AZD4248 + midazolam) to Reference (AZD4248) based on AUClast (RAUClast) of AZD4248Time frame: Days 1-2, 4-5, 17 and 18
  • AddedPart E: Ratio of Test treatment (AZD4248 + midazolam) to Reference (AZD4248) based on Cmax (RCmax) of AZD4248Time frame: Days 1-2, 4-5, 17 and 18
  • AddedPart E: Terminal elimination half-life (t½λz) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
  • AddedPart E: Terminal rate constant (λz) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
  • AddedPart E: Time to reach maximum observed concentration (tmax) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
  • AddedPart E: AUCinf for metforminTime frame: Days 2-4, 6, and 7-16
  • AddedPart E: AUClast for metforminTime frame: Days 2-4, 6, and 7-16
  • AddedPart E: Cmax for metforminTime frame: Days 2-4, 6, and 7-16
  • AddedPart E: Ratio of Test treatment (AZD4248 + metformin) to Reference (AZD4248) based on AUCinf (RAUCinf) of AZD4248Time frame: Days 2-4, 6, and 7-16
  • AddedPart E: Ratio of Test treatment (AZD4248 + metformin) to Reference (AZD4248) based on AUClast (RAUClast) of AZD4248Time frame: Days 2-4, 6, and 7-16
  • AddedPart E: Ratio of Test treatment (AZD4248 + metformin) to Reference (AZD4248) based on Cmax (RCmax) of AZD4248Time frame: Days 2-4, 6, and 7-16
  • AddedPart E: Renal clearance (CLR) for metforminTime frame: Days 2-4, and 6-8
  • AddedPart E: t½λz for metforminTime frame: Days 2-4, 6, and 7-16
  • AddedPart E: λz for metforminTime frame: Days 2-4, 6, and 7-16
  • AddedPart E: tmax for metforminTime frame: Days 2-4, 6, and 7-16
Nov 12, 2026
Secondary outcomes
11 time frame changed, 1 added, 5 description edited
What changed in the outcomes
  • AddedPart E: Number of AEs and SAEsTime frame: From Day 1 to Follow Up visit (Part E: up to 24 days)
  • Time frameArea under concentration-time curve from time 0 to infinity (AUCinf)Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17 → Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
  • Time frameArea under concentration-curve from time 0 to the last quantifiable concentration (AUClast)Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17 → Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
  • Time frameApparent total body clearance (CL/F)Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17 → Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
  • Time frameMaximum observed drug concentration (Cmax)Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17 → Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
  • Time frameTerminal elimination half-life (t½λz)Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17 → Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
  • Time frameTerminal rate constant (λz)Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17 → Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
  • Time frameTime delay between drug administration and the first observed concentration (tlag)Part A1 and A2: Days 1-7, Part A3: Days 1-3. → Part A1 and A2: Days 1-7, Part A3: Days 1-3; Part E: Days 4-5, and 17-19
  • Time frameTime of last quantifiable concentration (tlast)Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17 → Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
  • Time frameTime to reach maximum observed concentration (tmax)Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17 → Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
  • Time frameApparent volume of distribution based on the terminal phase (Vz/F)Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17 → Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
  • Time frameVolume of distribution at steady state (Vss)Part A1 and A2: Days 1-7, Part A3: Days 1-3. → Part A1 and A2: Days 1-7, Part A3: Days 1-3
  • DescriptionIndividual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1-t2)]: how it is measured was reworded
  • DescriptionIndividual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 [fe(t1-t2)]: how it is measured was reworded
  • DescriptionMaximum observed drug concentration (Cmax): how it is measured was reworded
  • DescriptionRenal clearance (CLR): how it is measured was reworded
  • DescriptionTime to reach maximum observed concentration (tmax): how it is measured was reworded
Nov 12, 2026
Title
A Study to Investigate Safety, Tolerability, PharmacokineticsPK, and PharmacodynamicsPD of AZD4248 in Healthy Participants and, Participants With Chronic Kidney DiseaseCKD and Type 2 Diabetes and to, Assess Home Measurements of Creatinine in a Non -Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Dec 25, 2026→Jan 29, 2027
    Study completion Dec 25, 2026→Jan 29, 2027
    Enrollment 124→192
    Eligibility 3 criteria edited
    What changed in the criteria
    • EditedParts A, B, and BE:
    • EditedAny positive result on Screening for serum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), Hebpatitis C virus antibody (HCVab), or human immunodeficiency virus (HIV).
    • EditedParts A, B, and BE:
    Primary outcomes 19 added
    What changed in the outcomes
    • AddedPart E: Area under concentration-time curve from time 0 to infinity (AUCinf) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
    • AddedPart E: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
    • AddedPart E: Maximum observed drug concentration (Cmax) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
    • AddedPart E: Ratio of Test treatment (AZD4248 + midazolam) to Reference (AZD4248) based on AUCinf (RAUCinf) of AZD4248Time frame: Days 1-2, 4-5, 17 and 18
    • AddedPart E: Ratio of Test treatment (AZD4248 + midazolam) to Reference (AZD4248) based on AUClast (RAUClast) of AZD4248Time frame: Days 1-2, 4-5, 17 and 18
    • AddedPart E: Ratio of Test treatment (AZD4248 + midazolam) to Reference (AZD4248) based on Cmax (RCmax) of AZD4248Time frame: Days 1-2, 4-5, 17 and 18
    • AddedPart E: Terminal elimination half-life (t½λz) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
    • AddedPart E: Terminal rate constant (λz) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
    • AddedPart E: Time to reach maximum observed concentration (tmax) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
    • AddedPart E: AUCinf for metforminTime frame: Days 2-4, 6, and 7-16
    • AddedPart E: AUClast for metforminTime frame: Days 2-4, 6, and 7-16
    • AddedPart E: Cmax for metforminTime frame: Days 2-4, 6, and 7-16
    • AddedPart E: Ratio of Test treatment (AZD4248 + metformin) to Reference (AZD4248) based on AUCinf (RAUCinf) of AZD4248Time frame: Days 2-4, 6, and 7-16
    • AddedPart E: Ratio of Test treatment (AZD4248 + metformin) to Reference (AZD4248) based on AUClast (RAUClast) of AZD4248Time frame: Days 2-4, 6, and 7-16
    • AddedPart E: Ratio of Test treatment (AZD4248 + metformin) to Reference (AZD4248) based on Cmax (RCmax) of AZD4248Time frame: Days 2-4, 6, and 7-16
    • AddedPart E: Renal clearance (CLR) for metforminTime frame: Days 2-4, and 6-8
    • AddedPart E: t½λz for metforminTime frame: Days 2-4, 6, and 7-16
    • AddedPart E: λz for metforminTime frame: Days 2-4, 6, and 7-16
    • AddedPart E: tmax for metforminTime frame: Days 2-4, 6, and 7-16
    Secondary outcomes 11 time frame changed, 1 added, 5 description edited
    What changed in the outcomes
    • AddedPart E: Number of AEs and SAEsTime frame: From Day 1 to Follow Up visit (Part E: up to 24 days)
    • Time frameArea under concentration-time curve from time 0 to infinity (AUCinf)Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17 → Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
    • Time frameArea under concentration-curve from time 0 to the last quantifiable concentration (AUClast)Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17 → Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
    • Time frameApparent total body clearance (CL/F)Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17 → Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
    • Time frameMaximum observed drug concentration (Cmax)Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17 → Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
    • Time frameTerminal elimination half-life (t½λz)Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17 → Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
    • Time frameTerminal rate constant (λz)Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17 → Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
    • Time frameTime delay between drug administration and the first observed concentration (tlag)Part A1 and A2: Days 1-7, Part A3: Days 1-3. → Part A1 and A2: Days 1-7, Part A3: Days 1-3; Part E: Days 4-5, and 17-19
    • Time frameTime of last quantifiable concentration (tlast)Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17 → Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
    • Time frameTime to reach maximum observed concentration (tmax)Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17 → Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
    • Time frameApparent volume of distribution based on the terminal phase (Vz/F)Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17 → Part A1 and A2: Days 1-7, Part A3: Days 1-3, Part B: Days 1-17. Part C: Days 1-17; Part E: Days 4-5, and 17-19
    • Time frameVolume of distribution at steady state (Vss)Part A1 and A2: Days 1-7, Part A3: Days 1-3. → Part A1 and A2: Days 1-7, Part A3: Days 1-3
    • DescriptionIndividual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1-t2)]: how it is measured was reworded
    • DescriptionIndividual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 [fe(t1-t2)]: how it is measured was reworded
    • DescriptionMaximum observed drug concentration (Cmax): how it is measured was reworded
    • DescriptionRenal clearance (CLR): how it is measured was reworded
    • DescriptionTime to reach maximum observed concentration (tmax): how it is measured was reworded
    Interventions Added Drug: Midazolam·Drug: Metformin. Arms added: Part E Drug-Drug Interaction Cohort
    Title A Study to Investigate Safety, Tolerability, PharmacokineticsPK, and PharmacodynamicsPD of AZD4248 in Healthy Participants and, Participants With Chronic Kidney DiseaseCKD and Type 2 Diabetes and to, Assess Home Measurements of Creatinine in a Non -Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants
    + 4 other changes: index terms, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07024823
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Jun 9, 2025
Primary completion
Jan 29, 2027 (estimated)
Completion
Jan 29, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion